Table 1.
Patient Characteristics
| Characteristics | n = 35 |
|---|---|
| Median age, y (25th to 75th percentile) | 60 (48–70) |
| Male | 28 (80%) |
| Race | |
| Caucasian | 28 (80.%) |
| Asian | 7 (20.0%) |
| Ethnicity | |
| Non-Hispanic/non-Latino | 33 (94.3%) |
| Hispanic/Latino | 1 (2.9%) |
| Not reported | 1 (2.9%) |
| ECOG performance status | |
| 0 | 15 (42.9%) |
| 1 | 18 (51.4%) |
| 2 | 2 (5.7%) |
| Most common sites of disease | |
| Nodes | 28 (80.0%) |
| Liver | 20 (57.1%) |
| Bone | 18 (51.4%) |
| Lung | 16 (45.7%) |
| Prior radiation | 15 (42.9%) |
| Number of prior systematic therapies | |
| 0 | 20 (57.1%) |
| 1 | 10 (28.6%) |
| 2 | 5 (14.3%) |
| Prior systematic therapies | |
| Vandetanib | 6 (17.1%) |
| Cabozantinib | 3 (8.6%) |
| Sunitinib | 1 (2.9%) |
| Tanespimycin | 1 (2.9%) |
| ARRY-401 | 1 (2.9%) |
| Octreotide | 4 (11.4%) |
| Zoledronic acid | 1 (2.9%) |
| Capecitabine | 1 (2.9%) |
| Topotecan + lapatinib | 1 (2.9%) |
| Radioiodine | 1 (2.9%) |
| Symptoms/alterations at registration | |
| Grade 2 hypertension | 1 (2.9%) |
| Grade 1 hypertension | 4 (11.4%) |
| Grade 2 fatigue | 4 (11.4%) |
| Grade 1 fatigue | 10 (28.6%) |
| Grade 1 anorexia | 4 (11.4%) |
| Grade 1 anemia | 10 (28.6%) |
| Grade 1 AST | 4 (11.4%) |
| Narcotic use | 9 (25.7%) |
| Hypertension medication use | 14 (40.0%) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group; AST, aspartate aminotransferase.